期刊
NATURE REVIEWS MOLECULAR CELL BIOLOGY
卷 20, 期 8, 页码 490-507出版社
NATURE PORTFOLIO
DOI: 10.1038/s41580-019-0131-5
关键词
-
类别
资金
- Allen Distinguished Investigator Award from the Paul G. Allen Frontiers Group
- US National Institutes of Health [R01DA036865, R01AR069085, R21NS103007, R33DA041878, P30AR066527, R41GM119914, R41AI136755, U01HG007900, UM1HG009428, UG3TR002142]
- National Science Foundation [EFRI-1830957, DMR-1709527]
- Pfizer-NCBiotech Distinguished Postdoctoral Fellowship
- Open Philanthropy
The prokaryote-derived CRISPR-Cas genome editing systems have transformed our ability to manipulate, detect, image and annotate specific DNA and RNA sequences in living cells of diverse species. The ease of use and robustness of this technology have revolutionized genome editing for research ranging from fundamental science to translational medicine. Initial successes have inspired efforts to discover new systems for targeting and manipulating nucleic acids, including those from Cas9, Cas12, Cascade and Cas13 orthologues. Genome editing by CRISPR-Cas can utilize non-homologous end joining and homology-directed repair for DNA repair, as well as single-base editing enzymes. In addition to targeting DNA, CRISPR-Cas-based RNA-targeting tools are being developed for research, medicine and diagnostics. Nuclease-inactive and RNA-targeting Cas proteins have been fused to a plethora of effector proteins to regulate gene expression, epigenetic modifications and chromatin interactions. Collectively, the new advances are considerably improving our understanding of biological processes and are propelling CRISPR-Cas-based tools towards clinical use in gene and cell therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据